526 related articles for article (PubMed ID: 24280021)
21. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
[TBL] [Abstract][Full Text] [Related]
22. Comparison of autonomic dysfunction in patients with Parkinson's Disease, progressive supranuclear palsy, and multiple system atrophy.
Malkiewicz JJ; Siuda J
Neurol Neurochir Pol; 2024; 58(2):193-202. PubMed ID: 38148738
[TBL] [Abstract][Full Text] [Related]
23. Low serum uric acid levels in progressive supranuclear palsy.
Oropesa-Ruiz JM; Huertas-Fernández I; Jesús S; Cáceres-Redondo MT; Vargas-Gonzalez L; Carrillo F; Carballo M; Gómez-Garre P; Mir P
Mov Disord; 2016 Mar; 31(3):402-5. PubMed ID: 26686202
[TBL] [Abstract][Full Text] [Related]
24. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
[TBL] [Abstract][Full Text] [Related]
25. Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy.
Hara K; Watanabe H; Ito M; Tsuboi T; Watanabe H; Nakamura R; Senda J; Atsuta N; Adachi H; Aiba I; Naganawa S; Sobue G
Parkinsonism Relat Disord; 2014 Feb; 20(2):157-61. PubMed ID: 24172606
[TBL] [Abstract][Full Text] [Related]
26. Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.
Constantinescu R; Andreasson U; Holmberg B; Zetterberg H
Acta Neurol Scand; 2013 Feb; 127(2):e8-12. PubMed ID: 22998191
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
Holmberg B; Johnels B; Blennow K; Rosengren L
Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
[TBL] [Abstract][Full Text] [Related]
28. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
Messina D; Cerasa A; Condino F; Arabia G; Novellino F; Nicoletti G; Salsone M; Morelli M; Lanza PL; Quattrone A
Parkinsonism Relat Disord; 2011 Mar; 17(3):172-6. PubMed ID: 21236720
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.
Fiorenzato E; Antonini A; Camparini V; Weis L; Semenza C; Biundo R
J Neural Transm (Vienna); 2019 Nov; 126(11):1437-1445. PubMed ID: 31432258
[TBL] [Abstract][Full Text] [Related]
30. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations.
Kroonenberg PM; Oort FJ; Stebbins GT; Leurgans SE; Cubo E; Goetz CG
BMC Med Res Methodol; 2006 Jun; 6():26. PubMed ID: 16772027
[TBL] [Abstract][Full Text] [Related]
31. Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Worker A; Blain C; Jarosz J; Chaudhuri KR; Barker GJ; Williams SC; Brown R; Leigh PN; Simmons A
PLoS One; 2014; 9(12):e114167. PubMed ID: 25463618
[TBL] [Abstract][Full Text] [Related]
32. Serum metabolomics study in a group of Parkinson's disease patients from northern India.
Nagesh Babu G; Gupta M; Paliwal VK; Singh S; Chatterji T; Roy R
Clin Chim Acta; 2018 May; 480():214-219. PubMed ID: 29474999
[TBL] [Abstract][Full Text] [Related]
33. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson's disease.
Krishnan S; Mathuranath PS; Sarma S; Kishore A
Neurol India; 2006 Sep; 54(3):268-72. PubMed ID: 16936386
[TBL] [Abstract][Full Text] [Related]
34. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
Rusz J; Bonnet C; Klempíř J; Tykalová T; Baborová E; Novotný M; Rulseh A; Růžička E
J Neurol; 2015; 262(4):992-1001. PubMed ID: 25683763
[TBL] [Abstract][Full Text] [Related]
35. A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.
De Pablo-Fernández E; Courtney R; Warner TT; Holton JL
JAMA Neurol; 2018 Aug; 75(8):1008-1012. PubMed ID: 29710120
[TBL] [Abstract][Full Text] [Related]
36. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes.
Schmidt C; Berg D; ; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Reichmann H; Ziemssen T
Mov Disord; 2009 Oct; 24(14):2136-42. PubMed ID: 19768815
[TBL] [Abstract][Full Text] [Related]
37. Enteric GFAP expression and phosphorylation in Parkinson's disease.
Clairembault T; Kamphuis W; Leclair-Visonneau L; Rolli-Derkinderen M; Coron E; Neunlist M; Hol EM; Derkinderen P
J Neurochem; 2014 Sep; 130(6):805-15. PubMed ID: 24749759
[TBL] [Abstract][Full Text] [Related]
38. Serum adiponectin levels between patients with Parkinson's disease and those with PSP.
Kataoka H; Sugie K
Neurol Sci; 2020 May; 41(5):1125-1131. PubMed ID: 31897945
[TBL] [Abstract][Full Text] [Related]
39. The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms.
Pellecchia MT; Longo K; Manfredi M; Lucetti C; Cossu G; Petrone A; Marconi R; Sensi M; Epifanio A; Eleopra R; Marchese R; Scaravilli T; Morgante L; Abbruzzese G; Bonuccelli U; Donati E; Pivonello R; Colao A; Barone P
Mov Disord; 2008 Jan; 23(2):190-4. PubMed ID: 18044703
[TBL] [Abstract][Full Text] [Related]
40. Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Santangelo G; Cuoco S; Pellecchia MT; Erro R; Barone P; Picillo M
J Neurol; 2018 Nov; 265(11):2602-2613. PubMed ID: 30178175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
